S & amp; s lost goodwill and net profit. Advertising loss loss 120 million

category:Global
 S & amp; s lost goodwill and net profit. Advertising loss loss 120 million


In April 25th, Ssha F Ai Faith disclosed the annual report, investors earlier worries have been confirmed: in 2017, Ssha F Ai Faith net profit almost halved, eye drops sales revenue dropped by about 70 million yuan, and directly to raise 50 million 620 thousand yuan goodwill loss! According to this rough calculation, the direct economic loss caused by this public opinion storm to Ssha F Ai Faith last year is at least 120 million yuan! Performance fell seriously last year The annual report shows: In 2017, revenue was 939 million yuan, down 4% from the same period. Net profit was 146 million yuan, down 46.92% compared to the same period, and earnings per share were 0.59 yuan. In addition, the revenue of eye drops in 2017 was 680 million yuan, while the revenue in 2016 was 750 million yuan. Picture source: visual China In the annual report, the company said that the significant decline in performance was due to the reduction of 50 million 620 thousand yuan of goodwill and the transfer of 83 million 570 thousand yuan to the current business income. On the same day, the first quarter of this year showed a bigger drop in revenue: In the first quarter, the company achieved operating income of 190 million yuan, down 15.52% compared to the same period last year. Net profit was 40 million 850 thousand yuan, down 18.4% compared with the same period last year, and the basic earnings per share were 0.16 yuan. Brainwashing ads have been questioned about false propaganda In December 2, 2017, the public number of the clove doctor published a year of mad sale of 750 million of the brainwashing medicine, please let the Chinese old man. The article quotes the statement and authoritative literature of many ophthalmologists, and proves that the SAP love eye drops for the prevention and treatment of cataracts is a big lie; it is the use of brainwashing marketing to harm the elderly, to delay the treatment and have the risk of blindness. A questionable screenshot of the advertisement On the 16 day of the month, he responded with a notice of 43 pages long and up to 2 words. Ssha F Ai Faith emphasized that his drug is effective and that Bendazac Lysine Eye Dropss indication is early senile cataract. The company completed the phase II multi center clinical trial in December 1995 and completed the phase III multicenter clinical trial in July 1998. The clinical results of stage II and stage III multicenter showed that Bendazac Lysine Eye Drops had a certain effect on retarding the development of senile cataract and improving or maintaining visual acuity, the total effective rate was 71.13% and 73.73% respectively. The efficacy of S & P eyedrop product has aroused a lot of external queries, and has also aroused public concern. The State Administration of food and Drug Administration (State Administration of food and Drug Administration) charged the Zhejiang provincial food and drug administration as an immediate review of the advertising content of the product, and required further strengthening of the supervision and supervision of drug advertising, strict examination procedures and standards for drug advertising, and strict approval of advertising. The fermentation of public opinion has also led to a fall in its share price. When the negative news had just been released, after the opening of December 4th, the shares fell, closing 22.91 yuan / shares, down 3.33%, 5 day closing 22.89 yuan / share, down 0.09%, and the 6 day closing 22.1 yuan / share, down 3.45%. In 3 days, the accumulative value of the market value was nearly 400 million yuan. Since then, the company stopped trading until the resumption of trading in December 18th, the stock price fell for two consecutive days, and the stock price fell more than 30% within two weeks after resumption. Ssha F Ai Faiths stock price trend No substantial improvement in R & D investment in 2017 In terms of financial data, the eye drops are a product of profiteering. The companys 2016 earnings report showed that the income of the company was 754 million yuan, its operating cost was only 40 million 780 thousand yuan, and its gross profit margin was as high as 94.59%. 2016 annual report data From the latest annual report of 2017, the gross profit margin has not been substantially increased in the case of reduced operating income by 9.1%, which is only 1.04% less than in 2016, and is still up to 93.55%. 2017 annual report data Every Xiaobian noted that in addition to low cost, high gross profit and other factors, its sales cost accounted for a high proportion, low R & D expenses accounted for also low external criticism. In the last 3 years, the proportion of advertising expenses accounted for 25% of the business income, and 31.87% in 1-9 months in 2017; at the same time, the proportion of R & D costs was pitiful in 2016, only 2.97% in 2016. The proportion of R & D investment in 2017